Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

Prostate

Volumn 36, Issue 1, 1998, Pages 39-44

  Tjoa, B A ^a   Simmons, S J ^a   Bowes, V A ^a   Ragde, H ^a   Rogers, M ^a   Elgamal, A ^a   Kenny, G M ^a   Cobb, O E ^a   Ireton, R C ^a   Troychak, M J ^a   Salgaller, M L ^b   Boynton, A L ^a   Murphy, G P ^a  

^a NORTHWEST HOSPITAL   (United States)

^b LLC   (United States)

Author keywords

Clinical trial; Dendritic cells; Immunotherapy; Long period of evaluation; Prostate cancer; Prostate specific membrane antigen; T cell

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEPTIDE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; THORAX RADIOGRAPHY;

ALKALINE PHOSPHATASE; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; CELLS, CULTURED; DENDRITIC CELLS; EVALUATION STUDIES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MONITORING, PHYSIOLOGIC; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0032526296     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6     Document Type: Article

References (8)

1. Morton DL, Foshag LJ, Hoon DSB: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-482.
2. Pardoll D: New strategies for active immunotherapy with genetically engineered tumor cells. Curr Opin Immunol 1992;4: 619-623.
3. Tjoa B, Erickson S, Barren RJ III, Ragde H, Kenny G, Boynton A, Murphy G: In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995;27:63-39.
4. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: T-cell therapy of prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
5. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP: Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997; 32:272-278.
6. Murphy GP, Troychak MJ, Cobb OE, Bowes VA, Kenny RJ, Barren RJ III, Kenny GM, Ragde H, Wolfert RL: Evaluation of PSA, free PSA, PSMA, and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer. Prostate 1997;33:141-146.
7. Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, Ragde H, Kenny GM, Barren RJ III, Bowes VA, Gregorakis AK, Holmes EH, Boynton AL: Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint® scanning in prostatic cancer patients. Prostate 1997;33:281-285.
8. Klein LA: Medical progress: Prostatic carcinoma. N Engl J Med 1979;300:824-826.